Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …

Current American Thoracic Society (ATS) standards promote the use of race and ethnicity-
specific reference equations for pulmonary function test (PFT) interpretation. There is rising …

Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial
hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk …

This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …

Hypersensitivity pneumonitis (HP) is a complex and heterogeneous interstitial lung disease
(ILD) that occurs when susceptible individuals develop an exaggerated immune response to …

Lung transplantation (LTx) can be a life-extending treatment option for patients with
advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic …

Background Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients
with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the …

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3
PH in the most recent classification system. Prevalence of these diseases is increasing over …

Efforts are underway to transition the current lung allocation system to a continuous
distribution framework whereby multiple factors are simultaneously combined into a …